The ABPI’s 2026 flagship Competitiveness Report finds that the UK has begun to reverse years of decline. Sustained delivery of government commitments will now determine whether the recovery holds: abpi.org.uk/media/news/2026/…
At today's Regulatory Science Symposium, our final panel session discussed how the UK can best use its regulatory framework to benefit patients.
Everybody wants to see the UK lead the world on access to innovative medicines.
At our regulatory science symposium, our colleague Jas Dhaliwal-Rahi talked about where the UK can improve its regulatory offer and lead internationally in regulatory innovation. @MHRAgovuk
At our Regulatory Science Symposium, the @MHRAgovuk talked about improvements it has made, including to approval times for new medicines, and a partnership with the US FDA that will support scientific exchange.
Today’s Regulatory Science Symposium brought together key innovation bodies.
The Regulatory Innovation Office removes barriers slowing new technologies
@ARIA_research prioritises the
scientific areas with greatest breakthrough potential
@LifeArc transforms lives of people with rare diseases
Together: scientific breakthroughs.
The ABPI's third Regulatory Science Symposium is under way today, exploring how the UK can lead on
regulatory innovation and scientific breakthroughs.
We will discuss where the UK's regulatory offer can be genuinely distinctive. @MHRAgovuk
A year ago, the UK was losing ground on pharmaceutical investment. Today the picture is more hopeful: £2bn of new investment committed since September 2025. But the recovery is not yet secure. Our 2026 competitiveness report benchmarks the UK against 12 markets: abpi.org.uk/publications/uk-…
Can the UK and Europe regain their place as top destinations for clinical trials?
ABPI Chief Executive Richard Torbett joins the @FT Global Pharma & Biotech Summit to discuss this important topic.
ABPI members save 20% off passes; email membership@abpi.org.uk for the code. 🧵(1/3)
📅 @FT Global Pharma & Biotech Summit | 10-11 Nov 2026 | Convene 22 Bishopsgate, London
The summit brings together the leaders, investors and policymakers shaping life sciences' next phase.
ABPI members save 20% off passes; email membership@abpi.org.uk for the code. (2/3)
Also speaking at the @FT Global Pharma & Biotech Summit:
➡️ Lawrence Tallon, CEO, MHRA
➡️ Shreeram Aradhye, President Development & CMO, Novartis
➡️ Kim Branson, Chief AI Officer, GSK
➡️ Nathalie Moll, DG, EFPIA
➡️ Peter Wickersham, VP & GM UK/Ireland, Gilead
Plus many more.
ABPI members save 20% off passes; email membership@abpi.org.uk for the code. (3/3)
It's Scottish party conference season and our colleagues are attending:
📍 Scottish Liberal Democrats Conference - 10 Oct
📍 SNP Conference - fringe event on 15 Oct, and the business breakfast with the First Minister on 16 Oct
📍 Scottish Greens Conference - 24–25 Oct
We'll be championing life sciences' contribution to Scotland's economy and patient outcomes.
Read our manifesto for health and growth in Scotland. abpi.org.uk/publications/abp…
Our new Competitiveness Report 2026 confirms the shift: £2 billion of new pharma investment has been committed to the UK since September 2025. Policy certainty and UK strengths in science, IP, and talent are driving this recovery. Now we must deliver on every commitment to keep the momentum going. 🇬🇧💊
thetimes.com/business/compan…
It's party conference season, and we're busy! At Labour and Conservative Conferences, we're hosting two must-see panel sessions with @TotalPolitics. Bring your questions and join the conversation. 🧵
📍 Labour Conference, Liverpool
Mon 28 Sept, 10:30–11:30, Room 4A (inside secure area)
"How Britain as a life sciences superpower can deliver for patients"
With ABPI President Russell Abberley. (1/2)
#PartyConference2026#LifeSciences
📍 Conservative Conference, Birmingham
Mon 5 Oct, 10:30–11:30, H&C Room (inside secure area)
"How can we regain the UK's competitive edge in life sciences?"
With ABPI Vice President Laura McMullin.
We'd love to see you there. (2/2)
.@NICEComms has switched how it measures treatment benefits. The shift from EQ-5D-3L to 5L could restrict access to medicines that improve quality of life without extending survival. We're calling for close monitoring. Read our latest on what's changing and why it matters 👇 #MedicinesAccess#niceeeeeeabpi.org.uk/media/blogs/2026…
The UK holds one of the richest health data assets in the world. Our new report sets out how the Health Data Research Service can turn that potential into a global research advantage for patients. Read the blog by Janet Messer 👇
abpi.org.uk/media/blogs/2026…@HDR_UK#HealthData#LifeSciences
'The NHS Federated Data Platform, the Single Patient Record and the Health Data Research Service – what are they, and how do they relate to the UK’s pharmaceutical industry?' We hear you ask... Well, let's explain: abpi.org.uk/media/blogs/2026…